Novartis and Arvinas Enter Strategic Partnership to Advance Prostate Cancer Treatment Development.

Digital art of a handshake between two corporate figures, with symbols of Novartis and Arvinas logos in the background, overlaying a futuristic laboratory working on prostate cancer treatment.

Novartis and Arvinas Forge Strategic Alliance to Advance Prostate Cancer Therapies In a significant move aimed at accelerating the development of innovative treatments for prostate cancer, pharmaceutical giant Novartis has entered into a strategic collaboration with biotech firm Arvinas. This partnership is poised to leverage the potential of targeted protein degradation technology to craft novel […]

Nurix Therapeutics: $175M Public Offering Priced at $15/Share

Nurix Therapeutics, Inc., a leading clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and immune disorders, has announced the successful pricing of its upsized public offering. The company will issue 10,166,667 shares of its common stock at a price of $15.00 per share, raising a total of approximately $175.0 million in gross proceeds. […]

Rakuten Medical: COX-2 Inhibition Reduces Photoimmunotherapy-Induced Edema in Mice (AACR 2024)

Rakuten Medical, Inc. recently presented a poster at the 115th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California, highlighting their groundbreaking study on managing edema following photoimmunotherapy. The presentation, which took place on April 8th, 2024, showcased the company’s innovative approach to reducing photoimmunotherapy-induced edema in mice through the […]

FDA Green-lights Novel Delivery Approaches for SK Life Science’s Xcorpi in Treating Adults with Partial-Onset Seizures.

An illustration of a medical professional demonstrating diverse methods of administering SK Life Science's Xcorpi to adults suffering from partial-onset seizures, in a bright, modern clinic setting.

FDA Expands Administration Options for SK Life Science’s Xcorpi in Adult Epilepsy Patients The U.S. Food and Drug Administration (FDA) has broadened the administration methods for Xcorpi (cenobamate tablets), an antiepileptic medication developed by SK Life Science. This recent approval allows for a more versatile use of Xcorpi in the treatment of partial-onset seizures in […]

Nuevocor Appoints John Lee, MD, PhD as Chief Medical Officer

Nuevocor, a pioneering pre-clinical stage biotechnology company focusing on developing innovative therapies for cardiomyopathies with abnormal mechanobiology, has announced the appointment of Dr. John Lee, MD, PhD, as its new Chief Medical Officer. Dr. Lee brings a wealth of expertise to Nuevocor, with an extensive background in both medical research and clinical practice. His addition […]

Mirum Grants Stock Options and RSUs to New Employees

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today reported that its Board of Directors’ Compensation Committee has granted inducement awards to nine newly hired employees. The grants, made under Mirum’s 2020 Inducement Plan, consist of non-qualified stock options to purchase an aggregate of 36,100 shares of the company’s common stock and 18,050 restricted stock units (RSUs). The […]

Invenra and Astellas Initiate Collaboration Aimed at Identifying Bispecific Antibody Treatments.

An illustration of two scientists in lab coats shaking hands in front of a large, futuristic laboratory, with a 3D model of a bispecific antibody floating between them, symbolizing the partnership between Invenra and Astellas.

Invenra, Astellas Launch Partnership Focused on Discovering Therapeutic Bispecific Antibodies In an ambitious move to broaden their scope in the development and discovery of innovative therapeutic antibodies, Invenra Inc., a biotechnology company specializing in the discovery of next-generation biopharmaceuticals, has joined forces with Astellas Pharma Inc., a global leader in the pharmaceutical industry. This collaboration […]

Pharma Loses Millions Due to Poor Customer Data Management

Pharmaceutical companies are losing significant revenue due to inadequate customer data management practices, according to a recent industry report. The study highlights that before exploring advanced solutions like AI models to mitigate revenue leakage, pharma organizations must first address fundamental issues in their data management strategies. Experts emphasize the importance of establishing a solid foundation […]

NeuroSense Partners with Lonza to Investigate Biomarkers in Neurodegenerative Conditions.

Digital illustration depicting Lonza and NeuroSense collaborating in a futuristic laboratory, surrounded by glowing biological markers and advanced equipment, exploring solutions for neurodegenerative diseases.

Lonza, NeuroSense Strike Deal Focused on Exploring Biological Markers for Neurodegenerative Diseases In a significant development for the field of neurology and biotechnology, Lonza and NeuroSense Therapeutics have announced a collaboration aimed at advancing the study of neurodegenerative diseases. This partnership seeks to leverage both companies’ expertise in exploring and identifying biological markers that could […]

Novartis Streamlines Global Development Team to Drive Strategic Focus

Swiss pharmaceutical giant Novartis is strategically realigning its global development team, aiming for a reduction of up to 680 positions, representing approximately 1-2% of the unit’s workforce. This move comes as the company sharpens its focus on key therapeutic areas and integrates recent acquisitions. The majority of the workforce adjustments are anticipated to occur in […]

Diakonos’ DC Vaccine Improves Survival in Phase 1 Glioblastoma Trial

Diakonos Oncology’s unique dendritic cell vaccine, DOC1021, has shown promising results in a Phase 1 trial for glioblastoma (GBM). The trial data, presented at the 2024 American Association for Cancer Research annual meeting on April 8, revealed that 12 out of 16 newly diagnosed GBM patients remained alive with no attributable serious adverse events at […]

Abbisko Enrolls Final Patient in Pimicotinib’s Phase III TGCT Trial

Abbisko Therapeutics Co., Ltd., a leading biotech company, has reached a significant milestone in the development of its novel CSF-1R inhibitor, pimicotinib. The company announced the successful completion of patient enrollment for the pivotal Phase III clinical trial, MANEUVER STUDY, which aims to evaluate the efficacy and safety of pimicotinib in patients with tenosynovial giant […]

FDA Sanctions Broadened Usage of Dovato for Adolescent HIV Patients

FDA Approves Expanded Indication for Dovato to Include Adolescent Patients with HIV In a significant advancement for the treatment of HIV among younger populations, the U.S. Food and Drug Administration (FDA) has officially approved the expanded use of Dovato, allowing its prescription for adolescent patients. This marks an essential step forward in offering more flexible […]

Top 10 Oncology Breakthroughs: Game-Changing Phase III Trials in Q1 2024

The first quarter of 2024 saw a flurry of activity in the oncology space, with several biopharma companies reporting promising Phase III clinical trial results. These successful studies could potentially translate into new treatment options for cancer patients, offering improved survival rates and enhanced quality of life. Among the notable achievements were positive data readouts […]

5 Cancer Drugs Ace Phase 3 Trials, Offering New Hope

The first quarter of 2024 saw a flurry of activity in the oncology space, with several biopharma companies reporting promising results from their Phase III clinical trials. These successful studies could potentially translate into new treatment options for cancer patients, offering improved survival rates and enhanced quality of life. Among the notable achievements were five […]

FDA Approves CAR-T Therapies for Early Multiple Myeloma Treatment

The FDA has expanded the approved indications for two groundbreaking CAR-T cell therapies, Abecma and Carvykti, offering new treatment options for patients with multiple myeloma. Bristol Myers Squibb and 2seventy bio’s Abecma is now approved for third-line treatment, while Johnson & Johnson and Legend Biotech’s Carvykti has received the green light for second-line use. These […]

FDA Approves Abecma, Carvykti CAR-T for Earlier Multiple Myeloma Treatment

The FDA has granted expanded approvals for two CAR-T cell therapies, offering new treatment options for patients with multiple myeloma. Bristol Myers Squibb and 2seventy Bio’s Abecma has been approved for third-line treatment, while Johnson & Johnson and Legend Biotech’s Carvykti has received approval for second-line treatment. These approvals represent a significant advancement in the […]

Johnson & Johnson Plans to Purchase Shockwave Medical to Bolster Its MedTech Unit

An illustration of two giant puzzle pieces fitting together, one labeled 'Johnson & Johnson' and the other 'Shockwave Medical', against a backdrop of high-tech medical equipment and heart health symbols, highlighting collaboration and growth in the medical technology industry.

Johnson & Johnson Set to Acquire Shockwave Medical, Aiming to Strengthen Company’s MedTech Division In a strategic move to bolster its position in the medical technology sector, Johnson & Johnson has announced plans to acquire Shockwave Medical. This acquisition is poised to significantly enhance Johnson & Johnson’s MedTech division, signaling the company’s commitment to innovation […]

MaaT Pharma Stock Coverage Initiated by Gilbert Dupont/Société Générale

MaaT Pharma, a clinical-stage biotech company pioneering the development of Microbiome Ecosystem TherapiesTM to improve survival outcomes for cancer patients, has announced that Gilbert Dupont, part of the Société Générale Group, has initiated coverage of its stock. As a leader in the field of microbiome-based therapeutics, MaaT Pharma’s innovative approach aims to harness the power […]

Sirona Biochem Raises $132,500 CAD in Private Placement Funding

Sirona Biochem Corp., a leading biotech company, has successfully closed its private placement, securing gross proceeds of $132,500 CAD. This significant investment will enable Sirona Biochem to further advance its innovative research and development programs, focusing on creating groundbreaking solutions for the biotech industry. With a strong commitment to scientific excellence and a proven track […]